Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + carboplatin + pemetrexed + pembrolizumab + nogapendekin alfa inbakicept
- Development stage
- Unknown
- Lead developer
- ImmunityBio
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This combination regimen is a multi-agent chemo-immunotherapy protocol being investigated by ImmunityBio for the first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC). It integrates the IL-15 superagonist fusion protein nogapendekin alfa inbakicept (NAI; Anktiva) with the PD-1 checkpoint inhibitor pembrolizumab and standard-of-care platinum-based chemotherapy (pemetrexed combined with either cisplatin or carboplatin). Nogapendekin alfa inbakicept is a first-in-class IL-15 receptor agonist complex designed to activate and expand CD8+ T cells and natural killer (NK) cells, mimicking the natural process of IL-15 transpresentation. Pembrolizumab works by blocking the interaction between PD-1 and its ligands, thereby restoring anti-tumor T-cell activity. The chemotherapy components provide direct cytotoxic effects by inducing DNA cross-linking (cisplatin/carboplatin) and inhibiting essential enzymes in the folate pathway (pemetrexed), which may also enhance the immunogenicity of the tumor. This five-drug regimen is currently being evaluated in the Phase 3 QUILT-2.023 clinical trial.
- Other names
- NAInogapendekin alfa inbakicept
02
Targets
DHFR (Dihydrofolate reductase)GART (GAR transformylase)IL2RB (IL-2 receptor beta chain)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)DNAIL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on cisplatin + carboplatin + pemetrexed + pembrolizumab + nogapendekin alfa inbakicept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + carboplatin + pemetrexed + pembrolizumab + nogapendekin alfa inbakicept.